PE20160201A1 - BENCIL-1H-PYRAZOLE [3,4-B] PYRIDINES AND THEIR USE - Google Patents
BENCIL-1H-PYRAZOLE [3,4-B] PYRIDINES AND THEIR USEInfo
- Publication number
- PE20160201A1 PE20160201A1 PE2016000026A PE2016000026A PE20160201A1 PE 20160201 A1 PE20160201 A1 PE 20160201A1 PE 2016000026 A PE2016000026 A PE 2016000026A PE 2016000026 A PE2016000026 A PE 2016000026A PE 20160201 A1 PE20160201 A1 PE 20160201A1
- Authority
- PE
- Peru
- Prior art keywords
- fluorine
- represents hydrogen
- methyl
- oxides
- salts
- Prior art date
Links
- RQMWVVBHJMUJNZ-UHFFFAOYSA-N 4-chloropyridin-2-amine Chemical compound NC1=CC(Cl)=CC=N1 RQMWVVBHJMUJNZ-UHFFFAOYSA-N 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 5
- 229910052731 fluorine Chemical group 0.000 abstract 5
- 239000011737 fluorine Chemical group 0.000 abstract 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 2
- 239000000460 chlorine Chemical group 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- YNVRFTUDHPLHJD-UHFFFAOYSA-N 1-benzylpyrazolo[3,4-b]pyridine Chemical class N1=CC2=CC=CN=C2N1CC1=CC=CC=C1 YNVRFTUDHPLHJD-UHFFFAOYSA-N 0.000 abstract 1
- GTPVKNOAYNWRKA-UHFFFAOYSA-N 3-[1-[(2,3-difluorophenyl)methyl]-5-fluoro-6-methylpyrazolo[3,4-b]pyridin-3-yl]-7,7-dimethyl-5h-pyrrolo[2,3-e][1,2,4]triazin-6-one Chemical compound N1=C(C=2N=C3C(C(C(=O)N3)(C)C)=NN=2)C=2C=C(F)C(C)=NC=2N1CC1=CC=CC(F)=C1F GTPVKNOAYNWRKA-UHFFFAOYSA-N 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente solicitud se relaciona con bencil-1 H-pirazolo[3,4-b]piridinas de formula (I), en la que R1 representa hidrogeno o fluor, R2 representa hidrogeno o fluor, R3 representa hidrogeno, cloro o fluor, R4 representa hidrogeno, cloro, fluor o metilo, con la condicion de que por lo menos dos de los radicales R1, R2, R3 o R4 son diferentes de hidrogeno, R5 representa hidrogeno o fluor, R6 representa metilo, R7 representa metilo, o R6 y R7 junto con el atomo de carbono al que se unen forman un anillo ciclopropilo, y los oxidos N, sales, solvatos, sales de los oxidos N y solvatos de los oxidos N o sales de los mismos. Es compuesto preferido: 3-[1-(2,3-difluorobencil)-5-fluoro-6-metil- 1 H-pirazolo[3,4-b]piridin-3-il]-7, 7 -dimetil-5, 7 -dihidro-6H-pirrolo[2,3-e][1,2,4]triazin-6-ona; entre otros. Dichos compuestos son utiles para el tratamiento de enfermedades cardiovasculares.The present application relates to benzyl-1H-pyrazolo [3,4-b] pyridines of formula (I), in which R1 represents hydrogen or fluorine, R2 represents hydrogen or fluorine, R3 represents hydrogen, chlorine or fluorine, R4 represents hydrogen, chlorine, fluorine or methyl, with the proviso that at least two of the radicals R1, R2, R3 or R4 are different from hydrogen, R5 represents hydrogen or fluorine, R6 represents methyl, R7 represents methyl, or R6 and R7 together with the carbon atom to which they are attached form a cyclopropyl ring, and the N oxides, salts, solvates, salts of the N oxides and solvates of the N oxides or salts thereof. The preferred compound is: 3- [1- (2,3-Difluorobenzyl) -5-fluoro-6-methyl-1 H-pyrazolo [3,4-b] pyridin-3-yl] -7,7-dimethyl-5 , 7-dihydro-6H-pyrrolo [2,3-e] [1,2,4] triazin-6-one; among others. These compounds are useful for the treatment of cardiovascular diseases.
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13175896 | 2013-07-10 | ||
| EP13175889 | 2013-07-10 | ||
| EP13175895 | 2013-07-10 | ||
| EP13175904 | 2013-07-10 | ||
| EP13175894 | 2013-07-10 | ||
| EP13175899 | 2013-07-10 | ||
| EP13175890 | 2013-07-10 | ||
| EP13175892 | 2013-07-10 | ||
| EP13175903 | 2013-07-10 | ||
| EP13175898 | 2013-07-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20160201A1 true PE20160201A1 (en) | 2016-05-06 |
Family
ID=51162805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016000026A PE20160201A1 (en) | 2013-07-10 | 2014-07-08 | BENCIL-1H-PYRAZOLE [3,4-B] PYRIDINES AND THEIR USE |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9605008B2 (en) |
| EP (1) | EP3019506A1 (en) |
| JP (1) | JP2016523944A (en) |
| KR (1) | KR20160030541A (en) |
| CN (1) | CN105745215A (en) |
| AP (1) | AP2016008970A0 (en) |
| AU (1) | AU2014289312A1 (en) |
| CA (1) | CA2917682A1 (en) |
| CL (1) | CL2016000030A1 (en) |
| CU (1) | CU20160004A7 (en) |
| DO (1) | DOP2016000006A (en) |
| EA (1) | EA201600096A1 (en) |
| GT (1) | GT201600002A (en) |
| IL (1) | IL243525A0 (en) |
| MX (1) | MX2016000258A (en) |
| PE (1) | PE20160201A1 (en) |
| PH (1) | PH12016500065A1 (en) |
| SG (1) | SG11201600038UA (en) |
| TN (1) | TN2016000006A1 (en) |
| TW (1) | TW201542569A (en) |
| UY (1) | UY35652A (en) |
| WO (1) | WO2015004105A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102012200349A1 (en) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituted fused pyrimidines and triazines and their use |
| JP6748113B2 (en) | 2015-05-06 | 2020-08-26 | バイエル・ファルマ・アクティエンゲゼルシャフト | Use of sGC stimulants, sGC activators alone or in combination with PDE5 inhibitors for treating digital ulcers (DU) associated with systemic sclerosis (SSc) |
| CA2989740C (en) | 2015-07-23 | 2023-07-11 | Bayer Pharma Aktiengesellschaft | Stimulators and/or activators of soluble guanylate cyclase (sgc) in combination with an inhibitor of neutral endopeptidase (nep inhibitor) and/or an angiotensin aii antagonist and the use thereof |
| WO2017107052A1 (en) | 2015-12-22 | 2017-06-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase stimulators |
| WO2017121700A1 (en) | 2016-01-15 | 2017-07-20 | Bayer Pharma Aktiengesellschaft | 1,3-disubstituted 1h-pyrazolo[3,4-b]pyridine derivatives and use thereof as stimulators of soluble guanylate cyclase |
| WO2017121692A1 (en) | 2016-01-15 | 2017-07-20 | Bayer Pharma Aktiengesellschaft | Substituted sulfamides and use of same |
| ES2985316T3 (en) | 2016-10-11 | 2024-11-05 | Bayer Pharma AG | Combination containing the sGC stimulator vericuguat and the mineralocorticoid receptor antagonist finerenone |
| CN109890379A (en) | 2016-10-11 | 2019-06-14 | 拜耳制药股份公司 | Combination product comprising sGC activator and mineralocorticoid receptor antagonist |
| EP3609883B1 (en) | 2017-04-11 | 2022-06-29 | Sunshine Lake Pharma Co., Ltd. | Fluorine-substituted indazole compounds and uses thereof |
| WO2018234488A1 (en) | 2017-06-23 | 2018-12-27 | Basf Se | SUBSTITUTED CYCLOPROPYL DERIVATIVES |
| TW202015676A (en) | 2018-05-15 | 2020-05-01 | 德商拜耳廠股份有限公司 | Use of 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
| WO2020164008A1 (en) | 2019-02-13 | 2020-08-20 | Bayer Aktiengesellschaft | Process for the preparation of porous microparticles |
| US11884672B2 (en) | 2019-05-14 | 2024-01-30 | Vertex Pharmaceuticals Incorporated | Modulators of alpha-1 antitrypsin |
| CN120754115A (en) * | 2025-05-23 | 2025-10-10 | 远大医药（中国）有限公司 | Eplerenone-containing composition, pharmaceutical preparation, preparation method and use thereof |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES8601208A1 (en) | 1984-11-26 | 1985-11-01 | Fordonal Sa | Prepn. of a pyrazine derivative as gastric secretion inhibitor |
| JPS63139949A (en) | 1986-12-02 | 1988-06-11 | Fuji Photo Film Co Ltd | Novel pyrazolone dye |
| SE8704248D0 (en) | 1987-10-30 | 1987-10-30 | Haessle Ab | MEDICAL USE |
| GB9314412D0 (en) | 1993-07-13 | 1993-08-25 | Rhone Poulenc Agriculture | New compositions of matter |
| AU5348396A (en) | 1995-05-01 | 1996-11-21 | Fujisawa Pharmaceutical Co., Ltd. | Imidazo 1,2-a pyridine and imidazo 1,2-a pyridezine derivati ves and their use as bone resorption inhibitors |
| EP0743066A3 (en) | 1995-05-16 | 1998-09-30 | Mitsui Pharmaceuticals, Inc. | Wound-healing agent |
| DE19642255A1 (en) | 1996-10-14 | 1998-04-16 | Bayer Ag | Use of 1-benzyl-3- (substituted-hetaryl) fused pyrazole derivatives |
| DE59713007D1 (en) | 1996-10-14 | 2009-06-25 | Bayer Healthcare Ag | NEW HETEROCYCLYLMETHYL-SUBSTITUTED PYRAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEART CIRCULATION DISEASES |
| US6451805B1 (en) | 1997-11-14 | 2002-09-17 | Bayer Aktiengesellschaft | Substituted pyrazole derivatives for the treatment of cardiocirculatory diseases |
| DE19834044A1 (en) | 1998-07-29 | 2000-02-03 | Bayer Ag | New substituted pyrazole derivatives |
| DE19834047A1 (en) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituted pyrazole derivatives |
| DE10021069A1 (en) | 2000-04-28 | 2001-10-31 | Bayer Ag | Substituted pyrazole derivative |
| ATE521353T1 (en) | 2000-10-23 | 2011-09-15 | Glaxosmithkline Llc | NEW TRIS-SUBSTITUTED 8H-PYRIDOÄ2,3-DÜPYRIMIDINE-7-ONE DERIVATIVE FOR THE TREATMENT OF CSBP/P38KINASE-MEDIATED DISEASES |
| AU2002221827A1 (en) | 2000-11-22 | 2002-06-03 | Bayer Aktiengesellschaft | Novel lactame-substituted pyrazolopyridine derivatives |
| DE10132416A1 (en) | 2001-07-04 | 2003-01-16 | Bayer Ag | New morpholine-bridged pyrazolopyridine derivatives |
| DE10220570A1 (en) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamate-substituted pyrazolopyridines |
| DE10232571A1 (en) | 2002-07-18 | 2004-02-05 | Bayer Ag | 4-amino substituted pyrimidine derivatives |
| DE602004029025D1 (en) | 2003-05-09 | 2010-10-21 | Asahi Glass Co Ltd | PROCESS FOR PREPARING 3-SUBSTITUTED 2-CHLORO-5-FLUORO-PYRIDINE BZW. A SALT OF IT |
| CN100355732C (en) | 2003-11-03 | 2007-12-19 | 上海药明康德新药开发有限公司 | Preparation of 2-Cl-5-F-nicotinate and nicotonic acid |
| MX2007009017A (en) | 2005-01-26 | 2007-09-19 | Schering Corp | 3-(indazol-5-yl)-(1,2, 4) triazine derivatives and related compounds as protein kinase inhibitors for the treatment of cancer. |
| US7541367B2 (en) | 2005-05-31 | 2009-06-02 | Janssen Pharmaceutica, N.V. | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders |
| CN101277960A (en) | 2005-09-29 | 2008-10-01 | 默克公司 | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| DE102006043443A1 (en) | 2006-09-15 | 2008-03-27 | Bayer Healthcare Ag | Novel aza-bicyclic compounds and their use |
| CN101790532B (en) | 2007-07-31 | 2013-11-20 | 沃泰克斯药物股份有限公司 | Preparation method of 5-fluoro-1H-pyrazolo [3,4-b ] pyridine-3-amine and derivatives thereof |
| JP2011513483A (en) | 2008-03-10 | 2011-04-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | Pyrimidines and pyridines useful as inhibitors of protein kinases |
| AU2009322836B2 (en) | 2008-11-25 | 2013-04-04 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| DE102009004245A1 (en) | 2009-01-09 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Novel fused, heteroatom-bridged pyrazole and imidazole derivatives and their use |
| AR076601A1 (en) | 2009-05-21 | 2011-06-22 | Chlorion Pharma Inc | PYRIMIDINS AS THERAPEUTIC AGENTS |
| WO2011115804A1 (en) | 2010-03-17 | 2011-09-22 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| DE102010021637A1 (en) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
| KR20140019004A (en) | 2010-05-27 | 2014-02-13 | 머크 샤프 앤드 돔 코포레이션 | Soluble guanylate cyclase activators |
| WO2011161099A1 (en) | 2010-06-25 | 2011-12-29 | Bayer Pharma Aktiengesellschaft | Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes |
| AU2011275825A1 (en) | 2010-07-09 | 2013-02-07 | Bayer Intellectual Property Gmbh | Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases |
| US8765769B2 (en) | 2010-07-09 | 2014-07-01 | Bayer Intellectual Property Gmbh | Ring-fused 4-aminopyrimidines and use thereof as stimulators of soluable guanylate cyclases |
| AP3445A (en) | 2010-08-31 | 2015-10-31 | Dow Agrosciences Llc | Pesticidal compositions |
| DE102010040233A1 (en) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclic aza heterocycles and their use |
| DE102010040234A1 (en) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Process for the preparation of 5-fluoro-1H-pyrazolo [3,4-b] pyridine-3-carbonitrile |
| DE102010043380A1 (en) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Benzyl-substituted carbamates and their use |
| WO2012152629A1 (en) | 2011-05-06 | 2012-11-15 | Bayer Intellectual Property Gmbh | Substituted imidazopyridines and imidazopyridazines and the use thereof |
| EP2699578B1 (en) | 2011-04-21 | 2016-04-20 | Bayer Intellectual Property GmbH | Fluoroalkyl-substituted pyrazolopyridines and use thereof |
| BR112013030909A2 (en) | 2011-05-30 | 2016-12-06 | Astellas Pharma Inc | imidazopyridine compounds |
| EP2729476B1 (en) | 2011-07-06 | 2017-08-23 | Bayer Intellectual Property GmbH | Heteroaryl substituted pyrazolopyridines and their use as stimulators of soluble guanylate cyclase |
| EP2763990B1 (en) | 2011-09-01 | 2017-02-22 | F. Hoffmann-La Roche AG | Pyrrolopyrazine kinase inhibitors |
| SG11201400083VA (en) | 2011-09-02 | 2014-06-27 | Bayer Ip Gmbh | Substituted annellated pyrimidine and the use thereof |
| DE102012200352A1 (en) * | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituted, fused imidazoles and pyrazoles and their use |
| DE102012200360A1 (en) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituted triazines and their use |
| DE102012200349A1 (en) * | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituted fused pyrimidines and triazines and their use |
| WO2013131923A1 (en) | 2012-03-06 | 2013-09-12 | Bayer Intellectual Property Gmbh | Substituted azabicycles and use thereof |
| CN105026405B (en) | 2013-03-01 | 2017-08-08 | 拜耳制药股份公司 | Pyrazolopyridine of benzyl substitution and application thereof |
| AU2014222739A1 (en) | 2013-03-01 | 2015-09-03 | Bayer Pharma Aktiengesellschaft | Trifluormethyl-substituted ring-fused pyrimidines and use thereof |
| CN105899510A (en) | 2013-08-08 | 2016-08-24 | 拜耳制药股份公司 | Substituted imidazo[1,2-a]pyrazinecarboxamides and use thereof |
-
2014
- 2014-07-08 PE PE2016000026A patent/PE20160201A1/en not_active Application Discontinuation
- 2014-07-08 WO PCT/EP2014/064547 patent/WO2015004105A1/en not_active Ceased
- 2014-07-08 KR KR1020167003065A patent/KR20160030541A/en not_active Withdrawn
- 2014-07-08 CN CN201480049852.8A patent/CN105745215A/en active Pending
- 2014-07-08 US US14/903,347 patent/US9605008B2/en not_active Expired - Fee Related
- 2014-07-08 EA EA201600096A patent/EA201600096A1/en unknown
- 2014-07-08 TW TW103123391A patent/TW201542569A/en unknown
- 2014-07-08 EP EP14736803.9A patent/EP3019506A1/en not_active Withdrawn
- 2014-07-08 AU AU2014289312A patent/AU2014289312A1/en not_active Abandoned
- 2014-07-08 MX MX2016000258A patent/MX2016000258A/en unknown
- 2014-07-08 CA CA2917682A patent/CA2917682A1/en not_active Abandoned
- 2014-07-08 AP AP2016008970A patent/AP2016008970A0/en unknown
- 2014-07-08 TN TN2016000006A patent/TN2016000006A1/en unknown
- 2014-07-08 UY UY0001035652A patent/UY35652A/en not_active Application Discontinuation
- 2014-07-08 SG SG11201600038UA patent/SG11201600038UA/en unknown
- 2014-07-08 JP JP2016524789A patent/JP2016523944A/en active Pending
-
2016
- 2016-01-07 DO DO2016000006A patent/DOP2016000006A/en unknown
- 2016-01-08 PH PH12016500065A patent/PH12016500065A1/en unknown
- 2016-01-08 GT GT201600002A patent/GT201600002A/en unknown
- 2016-01-08 CL CL2016000030A patent/CL2016000030A1/en unknown
- 2016-01-10 IL IL243525A patent/IL243525A0/en unknown
- 2016-01-11 CU CUP2016000004A patent/CU20160004A7/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GT201600002A (en) | 2018-12-19 |
| US20160145271A1 (en) | 2016-05-26 |
| DOP2016000006A (en) | 2016-02-15 |
| SG11201600038UA (en) | 2016-02-26 |
| JP2016523944A (en) | 2016-08-12 |
| CU20160004A7 (en) | 2016-06-29 |
| CN105745215A (en) | 2016-07-06 |
| US9605008B2 (en) | 2017-03-28 |
| TW201542569A (en) | 2015-11-16 |
| IL243525A0 (en) | 2016-02-29 |
| AU2014289312A1 (en) | 2016-02-11 |
| WO2015004105A1 (en) | 2015-01-15 |
| CL2016000030A1 (en) | 2016-08-19 |
| AP2016008970A0 (en) | 2016-01-31 |
| PH12016500065A1 (en) | 2016-07-04 |
| CA2917682A1 (en) | 2015-01-15 |
| EP3019506A1 (en) | 2016-05-18 |
| KR20160030541A (en) | 2016-03-18 |
| UY35652A (en) | 2015-01-30 |
| EA201600096A1 (en) | 2016-10-31 |
| TN2016000006A1 (en) | 2017-07-05 |
| MX2016000258A (en) | 2016-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20160201A1 (en) | BENCIL-1H-PYRAZOLE [3,4-B] PYRIDINES AND THEIR USE | |
| MX2022012313A (en) | OXISTEROLS AND METHODS OF USE THEREOF. | |
| ECSP19024046A (en) | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF TOLL-TYPE ENDOSOMAL RECEPTORS | |
| CO2018013978A2 (en) | Boronic acid derivatives and therapeutic uses thereof. | |
| CR20170573A (en) | BICYCLIC LACTAMAS AND METHODS OF USE OF THE SAME | |
| UY35898A (en) | ? SYK INHIBITING COMPOUNDS AND COMPOSITIONS THAT UNDERSTAND THEM ?. | |
| CL2017000992A1 (en) | Indole carboxamide compounds useful as kinase inhibitors | |
| UY35675A (en) | SUBSTITUTED DERIVATIVES OF QUINAZOLIN-4-ONA | |
| DOP2016000208A (en) | BENZIMIDAZOL-2-AMINAS AS MIDH1 INHIBITORS | |
| NI201600152A (en) | FUSED BICYCLIC HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | |
| MX2021007665A (en) | NOVELTY METHODS. | |
| CR20170575A (en) | NEW BICYCLIC DERIVATIVES, A PROCESS FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. | |
| UY35395A (en) | TETRACYCLIC BROMODOMINES INHIBITORS | |
| MX2018005890A (en) | COMPOSITIONS TO TREAT SPINAL MUSCLE ATROPHY. | |
| ECSP15012804A (en) | ALCOXYPYRAZOLES AS SOLUBLE GUANILATE CYCLASE ACTIVATORS | |
| CR20160337A (en) | NEW HETEROARILDIHYDROPIRIMIDINES 6-FUSIONATED FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | |
| CR20160518A (en) | COMPOUNDS TO TREAT SPINAL MUSCLE ATROPHY | |
| CR20170118A (en) | SPIRODIAMINE DERIVATIVES AS INHIBITORS OF ALDOSTERONA SINTASA | |
| MX367713B (en) | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISORDERS RELATED TO PHOSPHOINOSITIDE 3-KINASE DELTA. | |
| CR20150378A (en) | TETRACYCLIC COMPOUNDS REPLACED WITH HETEROCICLE AND METHODS OF USE OF THE SAME FOR THE TREATMENT OF VIVIC DISEASES | |
| MX2016015248A (en) | Imidazo[1,2-a]pyrazin-1yl-benzamide compounds for treating spinal muscular atrophy. | |
| MX2019003724A (en) | OXISTEROLS SUBSTITUTED IN C7 AND METHODS OF USE OF THE SAME. | |
| PE20160689A1 (en) | ISOCROMENE DERIVATIVES AS INHIBITORS OF PHOSPHOINOSITIDE-3 KINASES | |
| UY36677A (en) | TRICYCLIC COMPOUNDS AS ANTINEOPLASTIC AGENTS | |
| UY35551A (en) | HETEROARILE DERIVATIVES AS INHIBITORS OF ALDOSTERONA SINTASA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |